The observed ameliorative effects in DNCB-induced mice and TNF-ɑ stimulated HaCaT cells, coupled with their impact on key inflammatory mediators, empower continued exploration of this natural compound as a viable candidate for managing AD treatment in clinical practice. The gene discussed is TNF; the disease is Alzheimer disease.